Smartleaf Asset Management LLC Decreases Holdings in Haleon plc (NYSE:HLN)

Smartleaf Asset Management LLC trimmed its stake in Haleon plc (NYSE:HLN) by 25.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 21,713 shares of the company’s stock after selling 7,378 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Haleon were worth $206,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Addison Advisors LLC grew its holdings in Haleon by 28.7% during the fourth quarter. Addison Advisors LLC now owns 4,954 shares of the company’s stock valued at $47,000 after purchasing an additional 1,106 shares during the period. Synovus Financial Corp grew its stake in shares of Haleon by 0.8% during the 3rd quarter. Synovus Financial Corp now owns 148,834 shares of the company’s stock worth $1,575,000 after acquiring an additional 1,216 shares during the period. Greenleaf Trust increased its holdings in Haleon by 8.4% in the 4th quarter. Greenleaf Trust now owns 17,225 shares of the company’s stock worth $164,000 after acquiring an additional 1,333 shares during the last quarter. Baron Wealth Management LLC raised its stake in Haleon by 4.3% in the 4th quarter. Baron Wealth Management LLC now owns 33,632 shares of the company’s stock valued at $321,000 after acquiring an additional 1,381 shares during the period. Finally, Peapack Gladstone Financial Corp lifted its holdings in Haleon by 3.2% during the third quarter. Peapack Gladstone Financial Corp now owns 44,844 shares of the company’s stock valued at $474,000 after purchasing an additional 1,390 shares during the last quarter. 6.67% of the stock is owned by institutional investors.

Haleon Price Performance

HLN stock opened at $10.55 on Thursday. The firm has a 50 day moving average of $9.63 and a 200-day moving average of $9.85. The firm has a market capitalization of $47.74 billion, a P/E ratio of 31.01, a price-to-earnings-growth ratio of 2.82 and a beta of 0.28. Haleon plc has a 12 month low of $7.89 and a 12 month high of $10.80. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

Haleon (NYSE:HLN) last announced its quarterly earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. The firm had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. As a group, sell-side analysts predict that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The firm also recently declared a — dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be issued a $0.1166 dividend. The ex-dividend date is Friday, April 25th. This represents a dividend yield of 1.6%. This is a boost from Haleon’s previous — dividend of $0.05. Haleon’s dividend payout ratio (DPR) is presently 58.97%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Sanford C. Bernstein downgraded shares of Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Morgan Stanley lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Finally, HSBC restated a “hold” rating on shares of Haleon in a research report on Wednesday. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.